目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Hematologic Malignancies Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Hematologic Malignancies Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape

Chapter 4. Hematologic Malignancies Market: Disease Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Hematologic Malignancies Market: Disease Movement Analysis, 2023 & 2030 (USD Million)
4.3. Leukemia
4.3.1. Leukemia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Lymphoma
4.4.1. Lymphoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Myeloma
4.5.1. Myeloma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Hematologic Malignancies Market: Therapy Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Hematologic Malignancies Market: Therapy Movement Analysis, 2023 & 2030 (USD Million)
5.3. Chemotherapy
5.3.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Immunotherapy
5.4.1. Immunotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Targeted Therapy
5.5.1. Targeted Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Other Therapies
5.6.1. Other Therapies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Hematologic Malignancies Market: End Use Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Hematologic Malignancies Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
6.3. Hospital Pharmacies
6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Retail Pharmacies
6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Other
6.5.1. Other Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Hematologic Malignancies Market: Regional Estimates & Trend Analysis
7.1. Hematologic Malignancies Market Share, By Region, 2023 & 2030 (USD Million)
7.2. North America
7.2.1. North America Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. U.S. Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Canada Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.4. Mexico
7.2.4.1. Mexico Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2. U.K.
7.3.2.1. U.K. Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Germany Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.4. France
7.3.4.1. France Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Italy Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Spain Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.7. Denmark
7.3.7.1. Denmark Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.8. Sweden
7.3.8.1. Sweden Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.9. Norway
7.3.9.1. Norway Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.2. Japan
7.4.2.1. Japan Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.3. China
7.4.3.1. China Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4. India
7.4.4.1. India Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.5. Australia
7.4.5.1. Australia Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.6. South Korea
7.4.6.1. South Korea Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.7. Thailand
7.4.7.1. Thailand Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Brazil Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.3. Argentina
7.5.3.1. Argentina Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East and Africa
7.6.1. Middle East and Africa Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2. South Africa
7.6.2.1. South Africa Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Saudi Arabia Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.4. UAE
7.6.4.1. UAE Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Kuwait Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
8.4.1. Pfizer Inc.
8.4.1.1. Participant’s Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Recent Developments/ Strategic Initiatives
8.4.2. F. Hoffmann-LA Roche Ltd
8.4.2.1. Participant’s Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Recent Developments/ Strategic Initiatives
8.4.3. Sanofi SA
8.4.3.1. Participant’s Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Recent Developments/ Strategic Initiatives
8.4.4. Bristol-Myers Squibb Company
8.4.4.1. Participant’s Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Recent Developments/ Strategic Initiatives
8.4.5. AbbVie Inc.
8.4.5.1. Participant’s Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Recent Developments/ Strategic Initiatives
8.4.6. Novartis AG
8.4.6.1. Participant’s Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Recent Developments/ Strategic Initiatives
8.4.7. GlaxoSmithKline PLC
8.4.7.1. Participant’s Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Recent Developments/ Strategic Initiatives
8.4.8. Amgen Inc.
8.4.8.1. Participant’s Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Recent Developments/ Strategic Initiatives
8.4.9. Takeda Pharmaceutical Co. Ltd
8.4.9.1. Participant’s Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Recent Developments/ Strategic Initiatives
8.4.10. Johnson & Johnson
8.4.10.1. Participant’s Overview
8.4.10.2. Financial Performance
8.4.10.3. Product Benchmarking
8.4.10.4. Recent Developments/ Strategic Initiatives